Kumaril Bhargava, Ph.D., MBA, R.Ph., Founder

Kumaril Bhargava is the founder of Serentrix, LLC, a company developing compounds for pain.  Dr. Bhargava was part of the External Research & Development Innovation group at Merck and Pfizer where he played a key role in acquiring multiple technologies and companies and establishing collaborations with biotech firms and academia.  He also served as a Director of Strategic Marketing for Procrit™ at Johnson & Johnson. He has more than twenty years of experience in R&D, Supply Chain, Sales and marketing and Business development gained at Abbott, Wyeth/Pfizer, Johnson & Johnson and Merck.

Dr. Bhargava holds a Bachelor’s degree in Pharmacy from Birla Institute of Technology & Science, Pilani, India, a Ph.D. in Pharmaceutical Sciences, and an MBA from the University of Chicago.  He is a licensed pharmacist in the State of Pennsylvania and New Jersey.

Dr. Peter Sol Reinach, Ph.D, Chief Scientific Officer

Dr. Peter sol Reinach’s has co authored 168 peer reviewed scientific articles, written 10 book chapters and written 6 review articles dealing with the polymodal roles of transient receptor potential channels in ocular health and disease. Currently, his research activity has been cited by others nearly 6,000 times.  Besides he is a scientific reviewer of numerous peer reviewed journals and the member of several editorial boards. His research activities were continuously funded for more than 30 years from the National Eye Institute along with pharmaceutical contract and university departmental support. He continues to be a FARVO member of the Association for Research in Ophthalmology and Vision and also of the International Society of Eye Research.

His educational and professional background includes graduating from New York University  with a PhD in biophysics during which time he received an excellence award for his thesis outcome as well as a NSF fellowship to attend an international biophysics meeting in the former Soviet Union. His continuous National Eye Institute funding gave him the opportunity to broaden his research interests to initiate studies on receptor mediated control of responses underlying control of ocular epithelial renewal. He continued in this line of work after relocating to the State University of New York and also being appointed Adjunct Professor of Ophthalmology at Columbia University. During this tenure, he was course director of pharmacology instruction besides teaching various courses dealing with ocular diseases.

Dr. Glen Frick has over 25 years of drug development experience in the pharmaceutical industry with several first-time-in-human drug administrations under IND, CTA and CTNs. His experience in experimental and translational medicine is extensive in respiratory medicine, pain and neuroscience. He has developed and conducted several human experimental medicine models in Alzheimer’s Disease, pain, and COPD, as well as several proof-of-concept programs in these areas. He has been the point person in several face-to-face FDA meetings as well as having contributed to sNDA filings.

His educational training includes MD and PhD from State Univ of NY Downstate Medical Center, Brooklyn, NY and Thomas Jefferson University, Philadelphia, PA

Dr. Vijay Tammara, PhD, Consultant, Regulatory Affairs

Dr. Vijay Tammara is an experienced regulatory scientist with about 29 years of leadership experience in the field of regulatory science and strategic clinical drug development and made significant contributions to the approval of 9 Marketing Authorizations (BLAs and NDAs), 2 Biosimilar MAs in Emerging Markets, 3 ANDAs, 12 Orphan Drug Designations, 7 Qualified Infectious Drug Product Designations, and over 45 INDs.

Dr. Tammara received his Ph.D. in Pharmaceutics and Drug Delivery Systems from School of Pharmacy, Northeast Louisiana University, Monroe, LA.

Mr. Anupam Dokeniya, MBA, Consultant, Finance

Mr. Anupam Dokeniya has significant experience as CFO for multiple biotech companies and has been involved in M&A, fund raising and licensing.

Before entering the healthcare domain Anupam spent time at Santander Investments, Strategic Capital Management, and The World Bank, in addition to founding NSA Investments and Indus Partners. 

Mr. Dokeniya has MBA from American University, Washington, DC

Shashwat Sharad, PhD

Vice President, R&D and Project Management

Shashwat Sharad is a translational biomedical research scientist and management professional with 20+ years of experience in biomedical / oncology research, focusing on high-quality science to deliver innovation. Recognized as Co-inventor of a rapid diagnostic tester RightBiotic, the Fastest Antibiotic Finder and the fastest system for carrying out bacterial culture and sensitivity testing and provide report in just 4 hours as opposed to ~4days to address the challenges of antibiotic resistance.

He has two decades of experience working in the Healthcare domain and looking forward to managing the research priorities of the organizations, and adopting rational management strategies to inculcate positive change and innovation. Passionate about bridging the gap between complex scientific concepts and broader audiences. With a strong background in scientific research and a flair for storytelling, he specializes in translating complex medical information into engaging and accessible content.

Dr. Sharad holds a Master’s degree in Microbiology and a Ph.D. in Biochemistry.  During his Ph.D. he worked on the Mu-opioid receptor gene (oprm1) association with opiate addiction; and APOE & OB Genes anthropometric markers for Alzheimer’s and Type 2 diabetes.